Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that on general grounds [1706-1708,2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1706]
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1706]
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Research works printed but not linked: 3
- Reid, 1995, J Hum Hypertens, 9, S19
- Zamvil, 1990, Annu Rev Immunol, 8, 579, 10.1146/annurev.iy.08.040190.003051 · doi:10.1146/annurev.iy.08.040190.003051 · Paper page
- Cohen, 2003, Mult Scler, 9, S139
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“and that on general grounds [1706-1708, 2142] such a”
BackgroundIs multiple sclerosis a mitochondrial disease?
Mao, P., & Reddy, P. H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.002 · Cited by 243
“Furthermore, there are good scientific rationales for the use of combination therapy in MS, and the clinical trials are also currently underway to establish the therapeutic efficacy and safety of various combination therapies for MS patients [175] .”
Treatment and management of cognitive dysfunction in patients with multiple sclerosis
DeLuca, J., Chiaravalloti, N. D., & Sandroff, B. M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0355-1 · Cited by 212
Rudick, R. A., & Polman, C. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70082-1 · Cited by 144
Torke, S., Pretzsch, R., Häusler, D., Haselmayer, P., Grenningloh, R., Boschert, U., Brück, W., & Weber, M. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02204-z · Cited by 101
Self-citationHerges, K., Millward, J. M., Hentschel, N., Infante-Duarte, C., Aktas, O., & Zipp, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025456 · Cited by 98
“One promising strategy is the use of combination therapies based on drugs that may complement one another in order to provide additive benefit [9].”
BackgroundWu, C., Rauch, U., Korpos, E., Song, J., Loser, K., Crocker, P. R., & Sorokin, L. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804247 · Cited by 90
“During EAE, autoreactive myelin-specific CD4 T cells penetrate into the CNS and initiate destruction and demyelination processes executed by activated macrophages (1, 2).”
BackgroundLehmann-Horn, K., Kinzel, S., & Weber, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102048 · Cited by 81
“Interestingly, a recently completed placebo-controlled clinical trial testing a combination [116] of systemic and intravenous rituximab in patients with secondary progressive (SP)-MS failed to efficiently deplete B cells in the CSF and to modulate biomarkers of CNS inflammation and tissue destruction [117].”
BackgroundSelf-citationMultiple sclerosis: current treatment algorithms
Río, J., Comabella, M., & Montalbán, X. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328346bf66 · Cited by 94
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence
Häusser‐Kinzel, S., & Weber, M. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0396-6 · Cited by 52
“While the relative importance of these alterations in the B cell compartments thus largely remains speculative, the observed effects on B cells may be of great value when suitable sequential treatment algorithms are tailored for an individual patient [113].”
Self-citationCourtney, A., Treadaway, K., Remington, G. M., & Frohman, E. M. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.09.014 · Cited by 61
Self-citationGeladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
“Further, since MS relapse biology and continuous progression of MS are nowadays recognized to involve differential immunological and molecular cascades in different compartments, a clear assessment of BTK inhibition to control MS progression in the absence of focal CNS inflammation may pave the way into a new era of c…”
BackgroundSelf-citationMicroglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Geladaris, A., Häusler, D., & Weber, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073461 · Cited by 47
“For RRMS, huge progress has been made in the development of various diseasemodifying therapies, which effectively reduce the number and the severity of new relapses as well as MRI activity [2].”
BackgroundSelf-citationDybowski, S., Torke, S., & Weber, M. S. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5332 · Cited by 36
Self-citationTouil, T., Ćirić, B., Ventura, E. S., Shindler, K. S., Gran, B., & Rostami, A. M. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.04.030 · Cited by 33
“Introduction of a novel treatment that can be administered orally, and acts synergistically with existing therapies would be highly beneficial for the treatment of MS [3].”
BackgroundMerino, A. G., Fernández, Ó., Montalbán, X., de Andrés, C., & Arbizu, T. (2010) · Neurología · doi:10.1016/j.nrl.2010.03.006 · Cited by 41
Cellular remyelinating therapy in multiple sclerosis
Yang, J., Rostami, A. M., & Zhang, G. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.08.020 · Cited by 34
“, IFN-β, glatiramer acetate, and mitoxantrone), all with potential side effects and only mild to moderate efficacy [1,7].”
Weber, M. S., Prod’homme, T., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-29 · Cited by 30
“In general, for two agents to exert synergistic benefit, distinct mechanisms of action are desirable, while employing the same mechanism may increase the risk of antagonism [46].”
BackgroundSelf-citationBall, N. J., Cowan, B. J., & Hashimoto, S. A. (2008) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2008.01019.x · Cited by 27
“The Food and Drug Administration has approved six medications as disease-modifying agents for the long-term treatment of this autoimmune inflammatory disease of the central nervous system.(2) However, subcutaneous recombinanthuman interferon beta is the most frequently prescribed therapy in our practice as well as els…”
BackgroundBrand, R. M., Diddens, J., Friedrich, V., Pfaller, M., Radbruch, H., Hemmer, B., Steiger, K., & Lehmann‐Horn, K. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001117 · Cited by 23
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
Kretzschmar, B., Pellkofer, H., & Weber, M. S. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0639-4 · Cited by 23
Self-citationRuggieri, M., Pica, C., Lia, A., Zimatore, G. B., Modesto, M., Liddo, E. D., Specchio, L. M., Livrea, P., Trojano, M., & Avolio, C. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.04.032 · Cited by 22
“, 2005a,b) and humans (Costello et al., 2007).”
Bibollet‐Bahena, O., Cui, Q., & Almazán, G. (2009) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152409788452108 · Cited by 20
Update on the treatment options for multiple sclerosis
Niino, M., & Sasaki, H. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.75 · Cited by 17
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
Havla, J. B., & Hohlfeld, R. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01214-x · Cited by 16
“Several antibodies such as natalizumab, ocrelizumab, ofatumumab, and alemtuzumab are considered highly effective options for treating RRMS/ RMS allowing for effective control of disease activity [10].”
Merino, A. G., Fernández, Ó., Montalbán, X., de Andrés, C., & Arbizu, T. (2010) · Neurología (English Edition) · doi:10.1016/s2173-5808(10)70070-5 · Cited by 17
CASP-9: A susceptibility locus for multiple sclerosis in Italy
Andreoli, V., Trecroci, F., Russa, A. L., Valentino, P., Condino, F., Latorre, V., Nisticò, R., Pirritano, D., Giudice, F. D., Canino, M., et al. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.03.013 · Cited by 13
“Although beneficial, these two options fail to prevent the progression of disease in some patients; hence, there is the need to explore new strategies that not only limit inflammation and demyelination in the CNS but also prevent axonal loss (Costello et al., 2007).”
BackgroundMartínez‐González, A. E., & Piqueras, J. A. (2014) · Neurocase · doi:10.1080/13554794.2014.960425 · Cited by 13
Schipper, H. M., Arnold, D. L., Grand’Maison, F., Melmed, C., Moore, F. G. A., Levental, M., Su, H., Constantin, M., Stril, J.-L., & Godin, J. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000090 · Cited by 12
Daclizumab Treatment for Multiple Sclerosis
Kim, S. E. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.2.227 · Cited by 12
Weber, M. S., Waubant, E. L., & Zamvil, S. S. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.043 · Cited by 11
Self-citationShu, Y., Yu, Y., Wang, Y., Dai, Y., Li, X., Qiu, W., Lu, Z., Wu, A., Ruan, H., & Hu, X.-Q. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131445 · Cited by 7
Shirazi, A., Golab, F., Sanadgol, N., Barati, M., Salehi, R. M., Vahabzadeh, G., Shadalui, Z., & Zarchi, S. R. (2016) · The Neuroscience Journal of Shefaye Khatam · doi:10.18869/acadpub.shefa.4.2.47 · Cited by 5
Dianas farmacológicas en la esclerosis múltiple
Sánchez, G. M. V., López, M. D. C., Fernández, O. F., & Bueso, J. J. (2011) · Revista de Neurología · doi:10.33588/rn.5301.2011061 · Cited by 4
“La terapia dirigida hacia diferentes fases del proceso inmune de la esclerosis múltiple (EM) puede ser razonable en el desarrollo de nuevos tratamientos, empleando como estrategia la terapia combinada [1].”
MethodCorticosteroids for Multiple Sclerosis: II. Application for Disease-Modifying Effects
Shah, A., Eggenberger, E., Zivadinov, R., Stüve, O., & Frohman, E. M. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.07.009 · Cited by 4
“Once the physician has confirmed evidence of disease progression or breakthrough disease in a treatment-adherent patient, and without evidence of a drug-related neutralizing antibodies, it is appropriate to consider a variety of options for intensified treatment.(2,3) Perhaps one of the most contentious issues in MS t…”
BackgroundSelf-citationMilo, R., & Miller, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-285-8_73 · Cited by 3
Glatiramer acetate to treat multiple sclerosis
Guerre, J., & Ford, C. C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.029 · Cited by 1
Dolor lumbar: presentación atípica de esclerosis múltiple
Blanco, I. M., Sieira, E. R., & Méndez, L. G. (2013) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2013.06.008 · Cited by 1
Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity
Hofstetter, H. H., Stüve, O., & Hartung, H.-P. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.02.009 · Cited by 1
Self-citationDEFINING SUCCESS IN MULTIPLE SCLEROSIS: TREATMENT FAILURES AND NONRESPONDERS *
Greenberg, B. M., & Frohman, E. M. (2008) · Cited by 1
Self-citationPaterka, M. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8598
Khoshnam, M., & Freedman, M. S. (2014) · Wiley eBooks · doi:10.1002/9781118298633.ch5
Bhanegaonkar, A. J. (2012) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4833
Selwood, D. L. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731387389.793556727
Wang, X. (2025) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2025.38.4.reg.14387.1
Raafat, M. A., Al-Hasnaawei, S., Mousa, H. M., Malathi, H., Sahu, S., Prathiba, S., Singh, G., & Sinha, A. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70673
“Ultimately, therapeutics targeting the redox–neurosteroid axis may reshape the future landscape of MS treatment [312, 313].”
Clinical trials of multiple sclerosis therapies
Cohen, J. A., & Rudick, R. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.028
Metadata
- Authors
- Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E.
- Affiliations
- University of Ottawa (CA)
- VA North Texas Health Care System (US)
- University of California, San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Costello, Fiona
- Venue
- Current Opinion in Neurology
- Published
- 2007-06
- Volume
- 20
- Issue
- 3
- Pages
- 281-285
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W1994457578
- Cited by
- 46
- References
- 46
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, combination therapy, experimental autoimmune encephalomyelitis, neurorepair, neuroinflammation, disease activity, investigational drugs, clinical trials
- MeSH terms
- Glatiramer Acetate, Animals, Antibodies, Monoclonal, Clinical Protocols, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Immunologic Factors, Immunotherapy, Multiple Sclerosis, Peptides, Interferon-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.